Download Sample Brochure @ http://tinyurl.com/zo3gdh2 “Angina-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. Read Analysis @ http://www.marketintelreports.com/report/DIIR2016018/angina-angina-pectorisglobal-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2016

1. Angina (Angina Pectoris)-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2016
“Angina (Angina Pectoris)-Global API Manufacturers, Marketed and Phase III
Drugs Landscape, 2016”, provides comprehensive insights about the marketed
drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the
globe.
Published on - 01 January, 2016 | Number of pages : 100
Single User Price: $2000

2. A key objective of the Angina (Angina Pectoris) Report is to understand the
market and pipeline status of the drugs around the Angina (Angina Pectoris) to
explore the generic development opportunities, licensing opportunities and to
gain competitive advantage on designing pipeline strategies. The Angina (Angina
Pectoris) Report provides the historical and forecasted sales of the drugs till 2018.
The Report gives insights into patents providing the patent protection data and
marketing exclusivity of all the drugs across the Angina (Angina Pectoris). While
the leading brands, companies and chemicals are considered thoroughly, the
report also provides details on the Global API Manufacturers across the globe
covering Drug Master Filings of US, Europe and API Manufacturers in Asia
specifically China and India.
Click Here To Check Complete Report

3. Scope of Report:
 A snapshot of the global Market and Phase III therapeutics scenario for
Angina (Angina Pectoris).
 A review of the marketed products under prescription for Angina (Angina
Pectoris), regulatory information and marketing status.
 Coverage of global patent coverage and detailed commentaries on the US
patent challenges.
 Graphical representation of investigational products for patent expiry and
market exclusivities across the globe.
 Product profiles for marketed products for Angina (Angina Pectoris) with
complete description of mechanism of action, therapeutic class, target,
route(s) of administration and chemical details.

4.  Coverage of API Manufacturers for Angina (Angina Pectoris) drugs in the
United States, Europe and Asian Regions with location details.
 Coverage of Regulatory filings in the US, Europe, and Asia specifically
India and China for Angina (Angina Pectoris) drugs.
 Coverage of Route of Synthesis of Active Pharmaceutical Ingredient
associated with Angina (Angina Pectoris) drugs.
 Coverage of Angina (Angina Pectoris) Phase III pipeline products featuring
sections on product description, mechanism of action, Chemical details
and research & development progress.
 Coverage of the United States Drug Master File (US DMF) available for
Phase III Pipeline Drugs.
 Key discontinued Marketed products.
 Global Sales Figure to 2018.
Download
Sample Brochure

5. Reasons to buy:
 Evaluate the marketing status and exclusivity details of Angina (Angina
Pectoris) key products to exploit opportunities for generic drug
development opportunities.
 Identify and understand important and diverse types of therapeutics
under Phase III development for Angina (Angina Pectoris).
 Design effective counter-strategies to gain competitive advantage by
identifying the key patent expiry details and exclusivity with respect to
Angina (Angina Pectoris).
 API intelligence over marketed drugs for Angina (Angina Pectoris) and
gaining primary intelligence over active ingredients manufacturers across
the globe.
 API intelligence over leading Phase III Pipeline drugs.

6.  Develop and design strategies by identifying the API manufacturers for
Phase III Pipeline products to enhance and expand business potential and
scope.
 Understanding the scope of the Phase III Drugs with nil regulatory filings.
 Understanding the chemical route of synthesis of approved drugs for
Angina (Angina Pectoris).
 Uncovering opportunities in the rapidly growing US market.
Make an Inquiry
Before Buying

7. Angina (Angina Pectoris)-Global API Manufacturers,
Marketed and Phase III Drugs Landscape, 2016
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of Angina (Angina Pectoris)-Global API Manufacturers, Marketed and Phase III
Drugs Landscape, 2016 and future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click here to order a copy of Angina (Angina
Pectoris)- Market Report